SearchMegan Hooton serves as President of IQVIA Biotech, a specialized business unit within IQVIA dedicated to providing clinical development solutions for biotech and emerging biopharmaceutical customers. With more than 30 years of experience in managing global research and development operations across pharmaceutical and biotech sectors, Meg brings a wealth of operational and cross-cultural expertise to her role.
As President, Meg steers the strategic direction of IQVIA Biotech on a global scale. She is accountable for successful project delivery across all Biotech and MedTech clinical trials. Accountable for clinical teams, investigator site services, data services, and therapeutic divisions worldwide she ensures the smooth execution of clinical development programs.
Meg joined IQVIA in 2008 serving in many roles across multiple geographies. She led clinical operations then project management delivery units, initially in her native Australia, later expanding to Asia Pacific and the United States as the global therapeutic area head for oncology in 2017. She joined the IQVIA Biotech leadership team in 2021 as chief operating officer.
Starting her career as a registered nurse, with various stints in the private sector, academia, and the Royal Australian Navy Reserve, she joined the clinical team at Bristol-Myers Squibb in the oncology and immunology franchises. In addition to her nursing degree and specialization in Intensive Care and Coronary Care, Meg has a bachelor’s degree in Asian Studies from Monash University. She currently resides in New Jersey. Meg’s journey from nursing to global leadership exemplifies her dedication to advancing healthcare through clinical research and development. Her impact extends across borders, making her a valuable asset to the industry and IQVIA Biotech.